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LDHA-mediated ROS generation in chondrocytes is
a potential therapeutic target for osteoarthritis
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Muhammad Farooq Rai 1, Regis J. O’Keefe1, Gabriel Mbalaviele4, Jie Shen1 & Yousef Abu-Amer 1,5✉
The contribution of inflammation to the chronic joint disease osteoarthritis (OA) is unclear,
and this lack of clarity is detrimental to efforts to identify therapeutic targets. Here we show
that chondrocytes under inflammatory conditions undergo a metabolic shift that is regulated
by NF-κB activation, leading to reprogramming of cell metabolism towards glycolysis and
lactate dehydrogenase A (LDHA). Inflammation and metabolism can reciprocally modulate
each other to regulate cartilage degradation. LDHA binds to NADH and promotes reactive
oxygen species (ROS) to induce catabolic changes through stabilization of IκB-ζ, a critical
pro-inflammatory mediator in chondrocytes. IκB-ζ is regulated bi-modally at the stages of
transcription and protein degradation. Overall, this work highlights the function of NF-κB
activity in the OA joint as well as a ROS promoting function for LDHA and identifies LDHA as
a potential therapeutic target for OA treatment.
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Osteoarthritis (OA), a degenerative disease of the joint, isthe most prevalent musculoskeletal disorder affectingover 50 million in the United States and 200 cases
per 100,000 individuals globally, and the leading cause of
disability1–4. However, despite its prevalence and severity, there
are no curative or effective disease-modifying treatments for OA
owing to poor understanding of disease pathogenesis. In healthy
joints, mechanical loading and biochemical cues maintain
articular homeostasis via a balance between chondrocyte synth-
esis of anabolic factors like type II collagen and aggrecan, and
catabolic factors like matrix metalloprotease 13 (MMP13) and A
Disintegrin and Metalloproteinase with Thrombospondin motifs
(ADAMTS)5,6. Since extracellular anabolic matrix molecules are
extremely stable, reduction of catabolic enzymes may be sufficient
to inhibit OA disease progression, especially at early stages of
disease7. Several studies have shown that both the synovial fluid
and serum of OA patients have elevated levels of pro-
inflammatory mediators such as interleukin (IL)-1β8–10 that
drive the production of catabolic degradative enzymes in
chondrocytes11,12. Mechanistically, many inflammatory stimuli
converge upon the NF-κB pathway, considered the gatekeeper of
the inflammatory response in cells13,14. Thus, activation of NF-κB
is proposed to play a key role in OA progression by promoting
the expression of cartilage degrading genes and chondrocyte
dysfunction, though the mechanisms by which pathologic acti-
vation of NF-κB induces joint catabolism in OA are obscure.
Energy metabolism is an extremely important mediator of
cellular function often altered during disease states, especially
under chronic inflammatory conditions. It has been shown that
chondrocytes in OA cartilage undergo metabolic changes though
the role of these changes in disease pathology is unclear15–19.
Furthermore, recent work has indicated that chondrocytes can
undergo metabolic changes in response to various stimuli23,25,26.
Chondrocytes in vivo are proposed to rely heavily upon glyco-
lysis, with lower energy production coming from oxidative
phosphorylation (OxPhos) due to the relatively hypoxic envir-
onment they reside within18. Glycolysis, which is oxygen-inde-
pendent, generates ATP quickly but inefficiently, while TCA cycle
and electron transport chain (ETC) are extremely efficient at
energy production through OxPhos when oxygen is available,
though most cells during physiological conditions take advantage
of a combination of glycolysis and OxPhos20. However, stressed
cells, such as immune and cancer cells, paradoxically utilize gly-
colysis and fermentation to generate ATP even in the presence of
oxygen, i.e., aerobic glycolysis21–23. This altered cellular meta-
bolism is not only important for energy homeostasis, but likely
critical for altered cellular function and signaling24–26. We pro-
pose that inflammation-driven metabolic reprogramming is
important for sustaining and driving inflammatory response
pathways in chondrocytes, a paradigm for understanding their
co-regulation and relationship to disease.
The inflammatory response is also driven by myriad
factors14,27. Reactive oxygen species (ROS) are one such player
considered as potential OA disease culprits due to their ability to
modify proteins and lipids, damage DNA and other adverse
effects in cells28–31. While ROS play important signaling func-
tions in physiological states, elevated ROS present significant
pathologic risk as mediators of disease progression in OA32.
Furthermore, the production and elimination of ROS is closely
tied to metabolic pathways, with enzymes and substrates playing
dual roles in both ROS modulation and metabolic processing33,34.
Thus, we proposed that inflammation-mediated metabolic
shifts may underlie joint degradation in OA by promoting the
production of inflammatory and catabolic proteins through the
modulation of ROS in chondrocytes. We display that NF-κB
activation in OA drives metabolic reprogramming of
chondrocytes towards aerobic glycoylsis. We then show that this
metabolic reprogramming causes increased oxidative stress in the
cell in an lactate dehydrogenase A (LDHA)-mediated manner.
Finally, we demonstrate that metabolism-mediated oxidative
stress promotes catabolic changes via the expression of IκB-ζ
protein stabilization. Our findings highlight a relationship
between these various players and offer therapeutic modalities for
the treatment of OA.
Results
Inflammatory stimulation induces metabolic changes. We
initially sought to determine the effect of inflammatory cytokines
on chondrocytes in order to identify downstream therapeutic
targets. Treatment of primary murine chondrocytes with IL-1β, a
pro-inflammatory cytokine implicated in OA10, caused acid-
ification of media (Supplementary Fig. 1A), suggesting a shift in
cell metabolism akin to increased secretion of lactic acid via
lactate dehydrogenase (LDH)-mediated fermentation35. Primary
sternal chondrocytes were utilized immediately upon isolation
without any expansion to avoid de-differentiation and altered
metabolism. Next, mRNA sequencing showed that IL-1β caused a
significant increase in the expression of catabolic and inflam-
matory genes such as MMPs and Interleukins, while decreasing
the expression of chondrocyte anabolic factors such as aggrecan
(Fig. 1a (arrows); Supplementary Data 1), among many other
differentially regulated genes. Interestingly, when inflammatory
and immune pathways were filtered out, RNA-seq analysis
revealed a significant difference in several metabolic pathways in
the KEGG database36. Gene set analysis indicated a decrease in
OxPhos and other metabolic pathways (Table 1), that are
important for glucose metabolism. We further detected a sig-
nificant increase in expression of genes involved in glycolysis and
fermentation such as Hexokinase-2 and LDHA with a decrease or
no change in TCA cycle and ETC genes (Fig. 1b and Supple-
mentary Data 1). Overall, these results suggest a shift in glucose
metabolism of chondrocytes towards aerobic glycolysis.
We confirmed these findings by detecting elevated levels of
extracellular lactic acid in supernatant of IL-1β-treated cell
cultures (Supplementary Fig. 1B). Further, consistent with RNA-
seq data, using Seahorse assay, we detected increased glycolysis
and decreased OxPhos in response to IL-1β as measured by cell
respiration (Fig. 1c–g). In addition, these cells appeared to have
slightly altered, though insignificant, mitochondrial biogenesis
upon IL-1β treatment, potentially indicating a compensatory
response due to altered metabolic activity (Supplementary Fig. 1c).
These cells also displayed lower intracellular ATP levels with
inflammatory stimulation (Supplementary Fig. 1D). In accor-
dance with these metabolic and RNA-seq data, GLUT1 and
LDHA, the key enzyme involved in fermentation, were increased
upon inflammatory stimulation (Fig. 1h–i). In addition, chon-
drocytes subject to inflammation had increased expression and
activity of G6PD2, the rate limiting enzyme involved in the
oxidative phase of pentose phosphate pathway (PPP) and
modulation of NADPH levels (Fig. 1j, k and Supplementary
Fig. 1E) with no significant change in expression of TCA cycle
enzymes or non-oxidative phase of PPP (Supplementary
Fig. 1F–J).
We then examined if the metabolic shift was mediated by NF-
κB activation by IL-1β. Inhibition or deletion of IKK2, the classical
NF-κB kinase, was able to reverse the metabolic shifts observed
with IL-1β stimulation of chondrocytes (Fig. 1c–j, l; Supplemen-
tary Fig. 1B–D, and Supplementary Fig. 1F–J). Furthermore,
expression of constitutively active IKK2 (IKK2ca)51,52 in chon-
drocytes led to an increase in the expression of genes involved in
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glycolysis independent of cytokine stimulation, confirming direct
NF-κB-mediated effects (Supplementary Fig. 1K–M).
Finally, to determine the temporal regulation of metabolic
changes in response to inflammation, a time course of IL-1β
treatment of chondrocytes displayed that changes in metabolic
enzyme gene expression occurred within 6 h of treatment, indicating
that the shift in metabolism may occur soon after stimulation
(Supplementary Fig. 1N–U). Furthermore, measurement of ECAR
at these timepoints indicated that glycolytic activity was elevated at
similar timepoints (Supplementary Fig. 1V–W). These results
indicate an overall metabolic reprogramming of cellular glucose
metabolic processes in response to inflammation.
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NF-κB activation mediates injury-induced OA in mouse knee.
We surmised that in human OA patients, initial insults to the
joint promote low-grade inflammation and activate NF-κB
pathway to initiate disease progression, which is then sustained
chronically. We first confirmed activation of NF-κB in the MLI
model by performing surgery in 12-week-old transgenic mice
expressing luciferase reporter under the control of the NF-κB
promoter. In vivo bioluminescence imaging (BLI) showed that
NF-κB activity peaked around 1 week post surgery in the joint,
and was significantly higher in MLI compared to sham-operated
joints (Fig. 2a, b). NF-κB activation declined progressively in both
groups with time, but remained higher in MLI-operated com-
pared to sham-operated joints, suggesting a chronically activated
state within the joint space. Micro-computed tomography (μCT)
and radiographic analyses showed that mice subjected to MLI
developed subchondral bone sclerosis and decreased joint spacing
8 weeks after surgery (Fig. 2c, d; white arrows). These structural
changes were associated with loss of proteoglycans and fibrillation
of articular cartilage (Fig. 2e, green arrows), which mimic the
changes seen in human OA patients37. Furthermore, immuno-
histochemistry performed in joint sections showed increased p-
IKK2 expression in articular cartilage (Fig. 2f; arrows). Buttres-
sing the findings that NF-κB is activated in articular cartilage
during OA development (Fig. 2f), we show that expression of NF-
κB-induced catabolic enzymes is increased in cartilage of MLI
joints (Supplementary Fig. 2A–D).
We scrutinized the direct role of NF-κB activation in OA
pathogenesis via expression of IKK2ca. We and others have
reported previously that IKK2ca mimics a chronically activated
inflammatory state by activating NF-κB transcriptional machin-
ery in the absence of exogenous inflammatory stimuli38,39. We
confirmed that treatment of primary chondrocytes with IL-1β or
exogenous expression of IKK2ca in these cells both activated NF-
κB signaling (Fig. 3a). Expression of IKK2ca increased gene
expression of inflammatory cytokines such as IL-6 and catabolic
enzymes such as MMP13 and ADAMTS4 and pro-inflammatory
factors such as MCP-1 (Fig. 3b–f). IL-6 and MMP13 are highly
implicated in joint breakdown40–43 and will be used as surrogates
of inflammatory and catabolic gene expression throughout the
study.
Based on the in vivo finding that MLI chronically activates NF-
κB in articular cartilage and in vitro data displaying that NF-κB
drives catabolic genes involved in OA, we expressed adenoviral
IKK2ca in the joint and used LacZ expression as control. We
observed that IKK2ca expression in the joint caused a severe joint
degradation that resemble joints of end-stage rheumatoid
arthritis, with significant inflammatory infiltrate and complete
destruction of the femoral and tibial heads (Fig. 3g, arrows).
However, this does not resemble the pathology seen in OA,
suggesting that the inflammatory response in OA is more cell
specific and occurs in a chronic, low-grade manner. Thus, in
order to create a more specific model, we genetically expressed
IKK2ca in articular chondrocytes in adult mice using the
tamoxifen-inducible aggrecan (Acan1)-CreERT2. Histological
analysis of joints by safranin-O staining revealed significant
evidence of proteoglycan loss in articular cartilage of Acan1CreER,
IKK2caki/ki (IKK2caacan) mice compared to tamoxifen-treated
control mice (Fig. 3h; arrows). Gene expression in articular
cartilage of IKK2caacan mice knee joints displayed increased
expression of catabolic genes such as IL-6, MMP13, ADAMSTS4
and MCP-1 compared with wild-type (WT) mice (Fig. 3i–m).
Thus, constitutive activation of IKK2/NF-κB in chondrocytes is
sufficient to cause OA-like joint damage and resembles OA
changes induced by MLI. This does not suggest that chondrocytes
are the only source of inflammatory stimuli generated in the joint,
as other cells such as synovial cells and macrophages are also
contributors, but the inflammatory response of chondrocytes to
such stimuli is critical for cartilage degradation.
LDHA inhibition reduces catabolic activity by IκB-ζ protein.
NF-κB has many important physiological functions, making
chronic or systemic NF-κB inhibition detrimental due to wide-
spread side effects. We instead targeted the metabolic shift using
the LDHA inhibitor FX1144 to inhibit the final step of the aerobic
glycolytic pathway and observed significant inhibition of
inflammatory response genes such as IL-6 and MMP13 (Fig. 4a,
b). Inhibition of LDHA was not toxic to cells and did not affect
cell viability (Supplementary Fig. 3A, B). Supporting these find-
ings, LDHA inhibition by FX11 did not significantly decrease
cellular ATP levels as expected or change ECAR (Supplementary
Fig. 3C, D). It is likely that there is partial inhibition of LDHA,
Fig. 1 Inflammation promotes aerobic glycolysis in chondrocytes. RNA sequencing was performed on primary chondrocytes treated with IL-1β for 24 h
and compared to untreated chondrocytes. Volcano plots were generated representing catabolic and anabolic genes (a) and metabolic genes (b). (c, d)
Primary sternal chondrocytes were treated with IL-1β (10 ng/mL) in the presence or absence of IKK2i (10 μM) for 72 h prior to performing seahorse assay.
All values were normalized to cell viability of treatments relative to untreated cells as measured by MTT assay. c ECAR measurement in glycolysis stress
test (Injection 1: No treatment, Injection 2: Glucose, Injection 3: Oligomycin, Injection 4: 2-DG) or d OCR measurement in MitoStress test (Injection 1: No
treatment, Injection 2: Oligomycin, Injection 3: FCCP, Injection 4: Antimycin A/Rotenone) was performed on Seahorse Instrument. Measurements were
performed every 5min with per timepoint for each condition. Graphs shown in c, d are mean ± S.D. for 8 wells, representative of one of three independent
experiments. (Untreated= Blue, IL-1β= Red, IKK2i=Green, IKK2i+ IL-1β= Purple). e Quantification of glycolysis from one timepoint in Glycolysis Stress
Test or f–g quantification of basal respiration and maximal respiration for one timepoint each from MitoStress test (mean ± S.D. for n= 8 wells). e–g One-
way ANOVA was performed followed by Tukey’s Multiple Comparison’s test, with p-values indicated in figure. h–j IKK2f/f chondrocytes were infected with
adenoviral-GFP, or adenoviral-cre (labeled IKK2−/−), then treated with IL-1β (10 ng/mL) for 24 h. qPCR as performed for LDHA, GLUT1, and G6PD2. Data
shown is representative of one experiment out of three, with bars representing mean of duplicates. k G6PD activity was measured in primary chondrocytes
treated with IL-1β (10 ng/mL) for 24 h compared to untreated cells. Bars are mean ± S.D. for n= 4 biological replicates. Two-tailed unpaired Student’s t-test
was utilized for statistical analysis. l Deletion of IKK2 under the conditions described for panels h–j was confirmed by performing qPCR for IKK2, with bars
representing mean of duplicates.
Table 1 Top KEGG metabolic pathways significantly differing
with IL-1β treatment.
KEGG pathway Mean log2
fold change
p-value
Oxidative phosphorylation −2.9581 0.00178
Butanoate metabolism −2.2511 0.01604
Valine, leucine, and isoleucine
degradation
−2.1551 0.01702
Glutathione metabolism 1.92693 0.02858
Citrate cycle −1.7425 0.04515
Fatty acid metabolism −1.7062 0.04578
Propanoate metabolism −2.0355 0.02402
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and compensation by LDHB that allows for continued cell sur-
vival, as has been shown in other studies45. We then tested if
LDHA inhibitor directly decreases NF-κB transcriptional activa-
tion by utilizing NF-κB-luciferase reporter chondrocytes and
observed that surprisingly, LDHA inhibitor (24 h) did not alter
NF-κB activation by IL-1β (Supplementary Fig. 3E).
In light of these observations, we hypothesized that NF-κB-
induced LDHA activity reciprocally regulates expression of
inflammatory response genes via targeting downstream products
of NF-κB. A prime candidate was Nfkbiz, one of the most
significantly upregulated genes in our RNA-seq dataset upon IL-
1β stimulation (Fig. 1a), which encodes IκB-ζ, a pro-
inflammatory protein that has been shown to be important in
macrophages for production of a subset of inflammatory response
genes13,46,47. We identified that gene expression of Nfkbiz was
significantly elevated in joint articular cartilage at 4 weeks post
MLI (Fig. 4c). Confirming that this finding is inflammation-
mediated, mRNA expression of Nfkbiz upon treatment of
chondrocytes with IL-1β showed a significant and rapid increase,
which was NF-κB dependent since IKK2 inhibitor treatment was
able to significantly attenuate it (Fig. 4d). Protein levels of IκB-ζ,
which is not expressed in untreated cells, were significantly
increased upon treatment with IL-1β, while co-treatment with
IKK2 inhibitor greatly reduced it, corroborating gene expression
findings (Fig. 4e). Genetic deletion of Nfkbiz demonstrated that
IκB-ζ is essential for the expression of a subset of inflammatory
response genes such as IL-6 and MMP13 in chondrocytes, even
when NF-κB signaling is intact (Fig. 4f–g). This highlights IκB-ζ
as a critical player in the inflammatory response and OA cartilage
degradation.
Based on the findings that FX11 reduced gene expression of
catabolic genes independent of NF-κB activity, we proposed that
inhibition of LDHA may decrease IκB-ζ expression. FX11 did not
decrease gene expression of Nfkbiz induced by IL-1β (Fig. 4h) but
significantly decreased IκB-ζ protein level (Fig. 4e). These
observations together with our findings that chondrocytes under
basal conditions express the Nfkbiz gene but not IκB-ζ protein,
and that IL-1β is essential for IκB-ζ protein expression, suggested
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Representative image of Safranin-O staining from one mouse shows loss of articular cartilage and proteoglycans in IKK2caacan mice compared to littermate
controls. i–m Gene expression measurement from mRNA isolated from pooled articular cartilage of IKK2caacan mice (n= 3) compared to control mice (n=
3), due to small size of tissue sample. Representative data from one experiment out of two, with bars representing mean of technical duplicates.
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that IκB-ζ is regulated in a bi-modal manner transcriptionally and
post-transcriptionally by IKK2 and LDHA, respectively. Propos-
ing that IκB-ζ is likely regulated post-translationally, we displayed
that IκB-ζ is targeted to the proteasome for degradation since use
of proteasome inhibitor lead to accumulation of IκB-ζ even in the
absence of inflammatory stimuli (Supplementary Fig. 3F;
lanes 5, 7).
To confirm that inhibition of LDHA was responsible for
the decreased expression of catabolic genes, and not due to an off
target effect of FX11, LDHA was deleted from primary
chondrocytes using LDHAf/f cells. LDHA deficient cells
(LDHA−/−) displayed a significant decrease in expression of IL-
6 and MMP13, confirming that LDHA supports catabolic gene
expression (Fig. 4i–k). In addition, LDHA deletion lead to
significant inhibition of IκB-ζ protein expression induced by IL-
1β treatment (Fig. 4l). We then performed RNA sequencing to
compare gene expression in LDHA and Nfkbiz deficient to wild-
type chondrocytes treated with IL-1β. We identified many
overlapping genes in LDHA deficient and Nfkbiz deficient
chondrocytes, further suggesting that much of LDHA’s anti-
inflammatory properties are IκB-ζ dependent (Fig. 4m–o). Of
note, deletion of LDHA or use of FX11 did not significantly
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reduce lactate secretion (Supplementary Fig. 3G) or viability of
chondrocytes, likely due to LDHB compensation. This confirms a
previous report that deletion of both LDHA and LDHB is
required in some cell types to eliminate lactate production45,48.
We confirmed this proposition by using the LDH inhibitors
GSK2837808A and sodium oxamate, which can act on both
LDHA and LDHB. Indeed, both inhibitors were able to effectively
reduce lactate production (Supplementary Fig. 3H). Similarly,
deletion of LDHA alone was unable to significantly reduce lactic
acid secretion (Supplementary Fig. 3I). We also observed that
inflammatory stimulation had opposite effects on LDHB gene
expression levels, with IL-1β treatment reducing LDHB gene
expression (Supplementary Fig. 3J), yet residual activity of this
enzyme supported lactate production. This is also supported by
the fact that at the protein level, 24 h of IL-1β treatment did not
decrease LDHB levels (Supplementary Fig. 3K). Various LDH
inhibitors also did not affect protein levels, displaying the
availability of LDHB to compensate.
LDHA-NADH interaction propagates ROS induced by
inflammation. Next, to decipher the mechanism by which LDHA
modulates the expression of IκB-ζ and the inflammatory
response, we first determined that LDHA does not regulate
mRNA stability of Nfkbiz, suggesting that IκB-ζ is likely regulated
at or beyond the stage of translation (Supplementary Fig. S4A).
This is in agreement with previous publications that suggest that
IκB-ζ is not regulated at the level of mRNA stability49. Since
LDHA’s primary function is to generate lactate, we examined if
lactate levels can affect IκB-ζ stability and/or the inflammatory
response. Treatment of chondrocytes with lactate did not affect
IL-6 and slightly increased MMP13 gene expression, but had no
effect on IκB-ζ protein expression (Supplementary Fig. 4B–D).
We also observed that treatment of cells with super-physiological
amounts of pyruvate marginally decreased the inflammatory
response but not IκB-ζ protein levels (Supplementary Fig. 4E–G).
These results rule out lactate and pyruvate as major contributors
to IκB-ζ.
Next, since LDHA inhibitor FX11 is a partial NADH
analog44,50, we surmised that the mechanism of action is
dependent upon LDHA binding to NADH. Prior publications
in cell-free systems showed that LDHA bound to NADH can
promote electron donor activity of NADH to generate ROS
species, thus creating a ROS chain reaction51–53. Using the
DCFDA fluorescent probe, we show that IL-1β significantly
increased intracellular ROS production in an NF-κB-dependent
manner (Fig. 5a). More importantly, FX11 treatment abolished
ROS production (Fig. 5a).
There are several sources of ROS in the cell, though the most
likely sources upon inflammatory stimulation are either the
activity of NADPH oxidase (NOX) or mitochondrial activity.
NOX activity is dependent upon NADPH, generated via pentose
phosphate activity, which we have shown to be increased in
chondrocytes treated with IL-1β (Supplementary Fig. 1E). We
show that NOX2 and NOX4 are expressed in chondrocytes, with
NOX2 expression being upregulated following IL-1β treatment
(Fig. 5b, c). Interestingly, DPI, a NOX inhibitor, or 6-ANA, a PPP
inhibitor, greatly decreased the IL-1β-induced increase of ROS,
indicating that NOX activity is a critical component of IL-1β-
mediated ROS production (Fig. 5d). These results were further
confirmed by the use of Vas2870, a highly specific NOX inhibitor
(Supplementary Fig. 4H, I).
NADPH can also be consumed by ROS-reducing GSH
regenerating enzymes. The results of GSH:GSSG measurements
suggest PPP activity is likely increased to maintain GSH levels
and attempts to balance out the pro-ROS effect of IL-1β
(Supplementary Fig. 4J). FX11 causes a slight increase in GSH,
suggest a lower state of oxidative stress, likely due to overall lower
ROS in the cell.
We also measured levels of ROS generated in mitochondria
and observed increased mtROS upon IL-1β treatment (Supple-
mentary Fig. 4K), due to mitochondrial dysfunction displayed by
the decrease in OxPhos observed in Fig. 1. This dysfunction likely
contributes to increased NADH availability, as was previously
published54,55, further contributing to the propagation of ROS by
LDHA. However, use of FX11 did not decrease mtROS
production.
To confirm that the ROS-propagating function of LDHA is not
mediated by its enzymatic activity, but rather through interaction
with NADH, we utilized sodium oxamate, a pyruvate-analog
LDHA inhibitor, which should not interfere with LDHA-NADH
interaction. We show that this inhibitor had no effect on ROS
(Supplementary Fig. 4L), though at these concentrations it
significantly decreased lactate production (Supplementary
Fig. 3H) confirming inhibition of LDHA enzymatic activity.
Furthermore, we display that FX11 increased levels of NADH
relative to NAD in the cell, supporting our hypothesis that FX11
displaces NADH from LDHA and stops the donation of electrons
from NADH to free radicals (Fig. 5E). LDHA deletion also
reduced the amount of ROS generated in the cell upon IL-1β
stimulation (Supplementary Fig. 4M). Thus, we confirm that
blocking the NADH binding site on LDHA is critical for ROS
generation compared to the substrate binding site.
Finally, to rule out the potential role of the higher atmospheric
oxygen in modulating metabolism and the inflammatory response,
Fig. 4 LDHA regulates catabolic gene expression and IκB-ζ protein levels. a, b Primary chondrocytes were treated with IL-1β (10 ng/mL) and/or FX11
(40 μM) for 24 h. Bar graphs represent qPCR data for IL-6 and MMP13 expression with error bars representing mean ± S.E.M. of n= 5 experiments.
c Articular cartilage was isolated from knee joints of mice 4 weeks after undergoing sham or MLI surgery. Gene expression of Nfkbiz was measured by
qPCR, with bars representing mean ± S.D. from n= 4 mice. Two-tailed student’s t-test was performed. d Primary chondrocytes were treated with IL-1β
and/or IKK2i (10 μM) for 24 h. Gene expression of Nfkbiz was measured by qPCR. Bars represent mean ± S.E.M. from n= 3 independent experiments.
e Representative immunoblot for IκB-ζ from chondrocytes treated with IL-1β and/or IKK2i (10 μM) or FX11 (40 μM) for 24 h. f–g Primary Nfkbizf/f
chondrocytes were infected with adeno-GFP or adeno-cre (labeled Nfkbiz−/−), then treated with IL-1β (10 ng/mL) for 24 h. Gene expression of IL-6
and MMP13 was measured, with bars representing mean ± S.D. for n= 4 replicates per group, representative of one of three independent experiments.
h Primary chondrocytes were treated with IL-1β and/or FX11 (40 μM) for 24 h. Gene expression of Nfkbiz was measured. Bars represent mean ± S.E.M. for
n= 6 independent experiments. i–k Primary LDHAf/f chondrocytes were infected with adeno-GFP or adeno-cre (labeled LDHA−/−), then treated with IL-1β
(10 ng/mL) for 24 h. Gene expression of LDHA, IL-6, and MMP13 was measured. Bars represent mean ± S.E.M. from n= 3 independent experiments for
LDHA and MMP13, n= 4 for IL-6. l Representative image of immunoblotting performed for LDHA and IκB-ζ under the same conditions. m–o WT,
LDHA−/−, and NFKBIZ−/− chondrocytes were cultured with IL-1β treatment for 24 h and RNA sequencing was performed to compare gene expression to
control chondrocytes. m The number of common, significantly regulated genes in both sets was counted. n The common genes significantly upregulated in
both sets was counted. o The common genes significantly downregulated in both sets were counted. a–b, d, f–k One-way ANOVA followed by Tukey’s
multiple comparison’s test was performed. p-values displayed in figure.
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we wanted to determine if the same effects of inflammation and
LDHA inhibition on ROS occur in hypoxic conditions. We
observed that chondrocytes cultured and treated in hypoxia
exhibited similar inflammatory responses to IL-1β (Supplemen-
tary Fig. 5A–C). However, there was increased expression of
LDHA and production of lactate, suggesting a greater reliance
upon anaerobic glycolysis as expected under hypoxia. In addition,
ROS levels also changed with similar patterns as that observed in
normoxic culture conditions, although there was slightly more
ROS with IL-1β stimulation, likely due to increased LDHA activity
with hypoxia (Supplementary Fig. 5E). FX11 was still highly
effective however, highlighting that the effects of inflammation on
metabolism and ROS seen are independent of environmental
oxygen and originate from a cell intrinsic source. Finally, IκB-ζ
expression in response to IL-1β also resembled that seen during
normoxia (Supplementary Fig. 5F).
ROS species stabilize IκB-ζ to promote inflammatory response.
We then hypothesized that inflammation-induced LDHA activity
propagates ROS production to cause oxidative stress, leading to
stabilization of IκB-ζ, and that the protective effect of LDHA
inhibitor (FX11) may be occurring via restraining damaging ROS
species. Indeed, treatment of chondrocytes with ROS scavenging
molecule N-acetyl-cysteine (NAC) was able to decrease protein
levels of IκB-ζ induced by IL-1β and also decreased expression of
IL-6 and MMP13 (Fig. 6a–c). We also confirmed this effect using
DMSO, which has previously been shown to be a ROS scavenger
and anti-inflammatory compound56. Increasing concentrations of
DMSO reduced cellular ROS levels, IκB-ζ protein expression, and
gene expression of IL-6 and MMP13 (Fig. S6A–D). Furthermore,
all the treatments that were shown to decrease ROS such as
Vas2870 and 6-ANA also potently decreased expression of IL-6
and MMP13 (Fig. S6E–H).
To further confirm the role of ROS in promoting IκB-ζ
stability, chondrocytes co-treated with IL-1β and hydrogen
peroxide showed increased IκB-ζ protein compared to IL-1β
alone (Fig. 6d). In addition, hydrogen peroxide co-treatment with
IL-1β increased expression of IL-6 and MMP13, both IκB-ζ
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Fig. 5 LDHA interaction with NADH propagates ROS. a Primary chondrocytes were treated with IL-1β (10 ng/mL) in the presence or absence of IKK2i
(10 μM) or FX11 (40 μM) for 24 h. DCFDA assay was performed and fluorescence was measured by microplate reader to determine intracellular ROS
levels, displaying reduction in ROS levels. Results are representative of one experiment out of three, with bars representing mean ± S.D. for n= 8 wells.
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6-ANA (100 μM) or DPI (1 μM) for 24 h. DCFDA assay was performed and fluorescence was measured by microplate reader to determine intracellular
ROS levels, displaying reduction in ROS levels. Results are representative of one of three independent experiments, with bars representing mean ± S.D.
for n= 8 wells. e Chondrocytes were treated with IL-1β (10 ng/mL) for 36 h in the presence of absence of FX11 (40 μM). NAD+ and NADH levels
were measured in chondrocytes to calculate the NADH:NAD+ ratio in biological replicates. Data are pooled from three experiments for n= 6
biological replicates, with error bars representing mean ± S.D. a, d, e One-way ANOVA was performed followed by Tukey’s multiple comparison’s test.
b, c Two-tailed student’s t-test was performed. p-values displayed in figure.
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responsive genes (Fig. 6e, f). However, hydrogen peroxide alone
had no effect on IκB-ζ protein, indicating that NF-κB activation,
metabolic shift and ROS generation are critical parallel processes
for IκB-ζ expression and stabilization. Furthermore, hydrogen
peroxide co-treatment partially reversed the inhibitory effect of
FX11 on IκB-ζ in chondrocytes by increasing protein levels
relative to FX11 alone (Fig. 6g). Addition of hydrogen peroxide
was also able to reverse the inhibitory effect of LDHA deletion or
FX11 on IL-6 gene expression (Supplementary Fig. 6I, J),
supporting that the effect of LDHA inhibition was ROS-
mediated. Furthermore, sodium oxamate, which does not
interfere with NADH binding, had little effect on ROS or IL-6
gene expression induced by IL-1β, or IκB-ζ protein levels
(Supplementary Fig. 6K–M). However, GSK2837808A was able
to markedly reduce the expression of IL-6, possibly because it is
also a partial NADH analog (Supplementary Fig. 6N).
Deletion of LDHA in chondrocytes is protective against OA.
To validate the functional significance of our biochemical find-
ings, we generated a mouse model for chondrocyte-specific
deletion of Ldha (AcanΔLdha), which are predicted to decrease
ROS generation in response to inflammatory stimulation as well
as decrease IκB-ζ protein expression, thus protecting mice from
OA. Gene deletion was induced by feeding tamoxifen prior to
performing MLI surgery. Safranin-O staining of the knee joints
displayed improved cartilage integrity in the MLI joints of
AcanΔLdha (Fig. 7a, lower panels; black arrows) animals compared
with control MLI mice, indicating protection, while sham joints
did not show significant differences between the groups (Fig. 7a;
upper panels). Blinded OARSI scoring was performed to measure
the severity of OA in the safranin-O stained sections, displaying
significantly decreased OA severity with LDHA deletion (Fig. 7b).
Furthermore, IHC staining for MMP13 in these joints displayed
reduced MMP13 levels in the MLI joints of AcanΔLdha animals
compared to MLI joints of control animals (Fig. 7c), and the
number of hypertrophic chondrocytes, which are indicative of
damaged cartilage, appeared visually less in MLI sections of
AcanΔLdha animals.
LDHA inhibition reduces catabolic response of HAC. We then
sought to determine the translational significance of our findings.
We compared the gene expression profiles between well-
preserved lateral and highly damaged medial human knee
articular cartilage, confirmed by radiographic scoring and visual
observation during surgery, from patients who underwent TKA.
We observed a significant increase in LDHA (Fig. 8a) and G6PD2
(Fig. 8b) gene expression in damaged cartilage, indicating that
human articular chondrocytes (HAC) in OA likely also undergo a
metabolic reprogramming. In addition, damaged OA cartilage
samples have elevated MMP13 (Fig. 8c) and NFKBIZ (Fig. 8d)
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gene expression. To further validate our findings, we observed
that primary HAC isolated from knee joints underwent similar
metabolic changes when treated with IL-1β, with increased gly-
colytic activity and decreased peak oxygen consumption rate
(Fig. 8e, f). We then performed IHC in human OA cartilage
compared to healthy donors and observed increased staining for
IκB-ζ protein in the OA cartilage (Fig. 8g, arrows).
Next, we validated our results utilizing HAC, treated with
IKK2i or FX11 in the presence or absence of IL-1β. Treatment
with IL-1β increased gene expression of NFKBIZ, which was
significantly reduced with IKK2 inhibitor, but not with FX11
(Fig. 8h), replicating murine data (Fig. 4h). In addition, treatment
with IKK2 inhibitor was highly effective at reducing catabolic
enzyme and inflammatory cytokine production by inhibiting the
NF-κB pathway (Fig. 8i, j). FX11 had a similar inhibitory effect on
catabolic gene expression (Fig. 8i, j) as it did in murine
chondrocytes by reducing IL-6 and MMP13 expression (Fig. 4a,
b), identifying LDHA as a potential therapeutic target in human
OA patients as well.
Discussion
This work highlights several findings that have important
implications for understanding the intricate relationship between
the inflammatory and metabolic responses of OA chondrocytes.
We conclude that, (a) Inflammation shifts cell metabolism
towards aerobic glycolysis in an NF-κB-mediated manner, (b)
LDHA has a pro-ROS forming function in chondrocytes during
inflammatory states, (c) Inhibition of LDHA activity has potent
anti-inflammatory and anti-catabolic properties via increasing
degradation of IκB-ζ by the proteasome.
Unlike other joint diseases, such as RA, that have a significant
pathogenic contribution from immune and other joint synovial
cells, OA is primarily driven by the generation of catabolic pro-
ducts from articular chondrocytes in response to biomechanical
and inflammatory stimuli. Here, we present definitive data that
chronic NF-κB activation is one of the major drivers of patho-
logical changes in OA. NF-κB can be activated in chondrocytes
due to insults throughout life such as mechanical stress, injury,
and the presence of inflammatory cytokines emanating from
aging, metabolic disease and other causes to promote catabolic
changes. Cartilage degradation further increases mechanical stress
and injury to the joint, exacerbating inflammatory stimuli in the
synovial space to perpetuate NF-κB activity and generate a vicious
positive feedback cycle.
However, chronic systemic inhibition of NF-κB is challenging
in humans due to undesired side effects. Similarly, inhibition of
individual cytokines, such as IL-1β, using biologics has failed in
the past for treating OA since it does not block the myriad of
other potential inflammatory stimuli57. We instead explored a
paradigm by which inflammation and metabolism are recipro-
cally regulatory. IL-1β treatment caused metabolic reprogram-
ming, mimicking the Warburg effect and expanding upon some
previous reports studying chondrocyte metabolism58–60. Other
gene expression sets from articular chondrocytes treated with IL-
1β or OA chondrocytes also display similar alterations in meta-
bolic enzyme expression61,62, confirming metabolic changes as a
conserved aspect of OA. We highlight the metabolic shift is a
potential target for treating OA and identify a non-metabolic
function of LDHA that is critical for modulating the inflamma-
tory response, independent of its canonical lactate-producing
role. Chan et al. showed elegantly that LDHA binding to NADH
in a cell-free system can greatly increase the rate of oxidation and
free radical generation, causing a chain reaction that was
dependent upon superoxide as the initiating factor52,63,64. It is
likely that the interaction of NADH with the Rossman fold
domain of LDHA65,66 allows for faster electron donation from
NADH to oxygen-containing compounds through its catalytic
activity, as well as by thermodynamic stabilization of free radical
intermediates. A similar finding was reported by another group
studying the role of LDHA67, validating our own results. How-
ever, the impact of this finding in biological systems and its
implications for disease has not been well studied. While this
work suggests that NADH is a pathological factor, it is likely only
so during inflammatory states. During inflammation, elevated
glycolysis leads to increased NADH levels, which is not consumed
due to the decrease in ETC activity. Overall, this high-energy
NADH excess can donate electrons to oxygen-containing com-
pounds in addition to pyruvate. We propose however that this
mechanism is only partially responsible for the effect of FX11 on
inflammation since prior studies have shown that FX11 can also
have some effects on mitochondria44, which may explain why
deletion of LDHA did not have as dramatic of an effect on ROS as
FX11 treatment. More surprisingly, LDHA deletion or inhibition
had little effect on chondrocyte viability or lactate levels,
demanding further research into the role of other LDH isoforms
during inflammatory states.
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on contralateral leg and used as control. 10 weeks post surgery mice were
sacrificed and joints were collected for histology. Safranin-O staining was
performed of the MLI and sham joints. b OARSI scoring of two safranin-O
stained sections per mouse were averaged (n= 3 mice for control, n= 3
mice for AcanΔ/Ldha). Bars represents mean ± S.D. from one experiment out
of two comparing littermates. One-way ANOVA followed by Tukey’s test
multiple comparisons test was utilized for statistical analysis. c IHC was
performed for MMP13, with arrows pointing to examples of stained
chondrocytes. Representative images are displayed with pixel intensity of
stain quantified under each image. a, c Scale bar= 200 μm.
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Mechanistically, we provide evidence that IκB-ζ plays an
important part in the metabolic-inflammatory axis and is, at least
partially, responsible for the pro-inflammatory effects of LDHA-
induced ROS. IκB-ζ is an inflammatory mediator that we display is
bi-modally regulated by NF-κB and ROS, transcriptionally and
post-transcriptionally, respectively. The process begins with tran-
scriptional expression of Nfkbiz by IKK2/NF-κB followed by sta-
bilization of its protein product, IκB-ζ, in ROS-dependent manner.
We display that IκB-ζ is redox-sensitive protein essential for the
expression of a subset of inflammatory response genes, such as IL-
1β, MMP13 and IL-6, which are well established culprits of OA
cartilage loss, a finding supported by recent evidence68 and war-
rants discovery of direct inhibitors of IκB-ζ activity. One of the
limitations of this study was the use of fluorescent probes such as
DCFDA to study ROS production. The use of redox sensors would
offer much more fine-tuned analysis of ROS species. Further elu-
cidating this redox mechanism through state-of-the-art genetic
models and redox measurement techniques will be the focus of
future work, especially given the extensive evidence that oxidative
stress is a prevalent factor in OA pathogenesis31,69.
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Studies analyzing synovial fluid displayed that OA patients
have elevated levels of lactic acid in the absence of sepsis, further
supporting the notion that LDHA is likely a pathogenic player in
human OA70, which we confirmed using human OA tissue
samples. Our work has important translational implications given
that targeting LDHA may be very safe in humans. Humans who
have nonfunctional LDHA mutations are often asymptomatic or
have symptoms upon severe exertion71,72, suggesting that inhi-
bition of LDHA may not pose a significant detrimental effect to
healthy cells. It is possible that with specific targeting of FX11 or
NF-κB inhibitors to the joint, the progression of OA can be halted
by preventing chondrocyte-mediated inflammatory response.
Overall, our results identify LDHA-mediated ROS production as
a therapeutic target for OA.
Methods
Animal models. IKK2ca (IKK2caf/f,), LDHA floxed (Ldhaf/f) (gift from Dr. Fanxin
Long) on a C57BL/6 background were crossed with Aggrecan-cre–ERT2 mice
(Stock No. 09148, Jackson Labs) to generate Agn1CreERT2,IKK2caki/ki (IKK2caacan)
mice, AcanΔLdha, on a C57BL/6 background, respectively. Only male mice were
utilized for these experiments in order to maintain comparability to the MLI
model, which is generally performed on male mice. All mice were fed with
tamoxifen chow (Teklad Custom Diet, Envigo) to induce genetic recombination in
inducible Aggrecan-cre-ERT2 mice, with groups separated into cre-positive and
cre-negative animals. NF-κB-GFP-Luciferase reporter mice were purchased from
Jackson Labs. IKK2 floxed, LDHA floxed, and Nfkbiz floxed mice (68RBRC06410,
Riken, Japan) were used for isolating primary chondrocytes from newborn pups.
NF-κB-GFP-Luciferase reporter mice (Stock No. 027529, Jackson Labs) were used
for in vivo bioluminescence imaging with MLI and for isolating primary chon-
drocytes for measuring NF-κB activity. Wild type (WT) mice were generated by
breeding C57BL/6 animals. All experiments were performed using littermate
controls. Mice were housed at the Washington University School of Medicine
barrier facility at five or less per cage at 24–26 °C with humidity ranging between
30–60% with 12 h light/dark cycles switching at 6 p.m. All experimental protocols
were carried out in accordance with the ethical guidelines approved by the
Washington University School of Medicine Institutional Animal Care and Use
Committee.
Cell culture. For all chondrocyte experiments unless otherwise stated, primary
chondrocytes were isolated from the sterna and ribs of P1-P3 mice without con-
sideration for sex using sequential digestion with pronase (2 mg/mL, PRON-RO,
Roche) at 37 degrees, followed by collagenase D (3 mg/mL, COLLD-RO, Roche)
two times at 37 degrees, and cultured in Dulbecco's modified Eagle medium
(DMEM; Life Technologies, USA) containing 10% fetal bovine seru (FBS) and 1%
penicillin/streptomycin (15140122, ThermoFisher) and plated in tissue culture
plates, based on previous protocol73. For experiments, cells are treated with
recombinant mouse IL-1β (211-11B, Peprotech) at 10 ng/mL, LDHA inhibitor
FX11 (427218, EMD Millipore), Sodium Oxamate (O2751, Sigma), GSK2837808A
(MedChem Express), IKK2 Inhibitor SC-514 (SML0557, Sigma), Diphenyleneio-
dinium (D7008, Sigma), 6-aminonicotinamide (A68203, Sigma), Vas2870
(SML0273, Sigma) or hydrogen peroxide (323381, Sigma). IKK2ca expression
experiments were performed under similar conditions without treatment of IL-1β
following retroviral transduction. Human chondrocytes were isolated from post
surgery discarded human articular cartilage samples isolated by enzymatic diges-
tion. Cells were cultured in DMEM:F12 (Life Technologies, USA) containing 10%
FBS, 1% penicillin/streptomycin (15140122, ThermoFisher) and Ascorbic acid. To
generate retroviral particles, Plat-E cells were used. Plat-E cells were
cultured in DMEM supplemented with 100 units/mL penicillin/streptomycin
and 10% FBS (v/v).
Meniscal-ligamentous injury. Meniscal-ligamentous injury (MLI) surgery was
utilized to induce OA in mice74. In this procedure, medial meniscus was surgically
removed from the joint without disrupting patella or other ligaments. Sham sur-
gery was performed on the contralateral joint in which a similar incision is made
on the medial side without removal of the meniscus. After 10 weeks, mice are
sacrificed and joints were collected for histology. MLI was performed in 10–12-
week-old male NF-κB-GFP-Luciferase reporter mice to generate and analyze NF-
κB activation in OA model. AcanΔLdha mice underwent MLI surgery to study the
role of LDHA deletion on OA development. Mice were anesthetized with ketamine
according to the approved animal protocol. To analyze the effect of IKK2 inhibitor
VIII (HY-13060, Medchem Express, Monmouth Junction, NJ) on OA develop-
ment, MLI surgeries were performed in 12-week-old C57BL/6 WT mice. The mice
were injected with IKK2 inhibitor VIII (2 mg/kg, IP) every alternate day for
5 weeks. OARSI scoring was performed by blinded reviewer based on safranin-O
stained images observing articular cartilage structure and integrity. For isolation of
articular cartilage from these mice to study gene expression changes in the MLI
compared to sham joints, mice were sacrificed 4 weeks post surgery and articular
cartilage was scraped from the surface of femur and tibia of either sham or MLI
joints under dissection microscope. Cartilage was then immediately placed in
Trizol (15596026, ThermoFisher) and mRNA was isolated.
Adenoviral injection in joints. Adeno-LacZ and Adeno-IKK2ca viral particles
were purchased from Viraquest, Inc., North Liberty, IA. 1 × 109 particles (3–4 × 107
p.f.u.) Adeno-LacZ and Adeno-IKK2ca particles were injected in left and right
knee, respectively, of 6-week-old C57BL/6 mice. The mice were sacrificed 10 days
after injection. The joint tissues were collected and processed for histology and
immunohistochemistry.
Histology and immunochemistry. At the end of experiments, mouse long bones
were harvested keeping knee joints intact and fixing in 10% neutral buffered for-
malin for 24 h at room temperature followed by decalcification in Immunocal
(StatLab, McKinney, TX) for 3 days with fresh Immunocal changed every 24 h.
Tissues were processed, embedded into paraffin, and sectioned 5 μm thick then
stained with Hematoxylin-Eosin or Safranin-O to visualize cartilage and bone. For
immunohistochemistry, sections were deparaffinized and rehydrated using three
changes of xylenes followed by ethanol gradient. Antigen retrieval in murine sec-
tions was performed by boiling samples in Citrate buffer (pH 6.0) at high pressure,
followed by quenching of endogenous peroxidase activity by incubation in 3%
H2O2 for 15 min at room temperature. Antigen retrieval in human cartilage sec-
tions was performed using proteinase K incubation for 15 min followed by per-
oxide quenching. Sections were then blocked using DAKO solution with
background reducing components (S302281, Agilent, Santa Clara, CA) for 1 h at
room temperature. Sections were incubated overnight at 4 degrees with anti-p-
IKK2 (ab5915, Abcam, Cambridge, UK), anti-MMP13 (Ab39012, Abcam, Cam-
bridge, UK), or anti-IκB-ζ (NBP1-89835, Novus, Colorado, US) antibody at a 1:200
dilution. Sections were rinsed in phosphate-buffered saline (PBS) several times
followed by addition of 1:500 dilution of biotinylated secondary antibody (BP-
1100, Vector Biolabs, Burlingham, CA) for 1 h. Post secondary antibody incuba-
tion, sections were washed with PBS-T several times followed by incubation with
streptavidin-HRP (2 μg/mL) for 20 min. After extensive washing with PBS, sections
were developed using DAB peroxidase kit (SK4100, Vector Biolabs, Burlingham,
CA), with development on each slide standardized to the same amount of time.
Images were quantified using ImageJ (RRID: SCR_003070) by converting images to
greyscale, followed by setting a threshold value and measuring and summing total
pixel intensity above the threshold.
Bioluminescence imaging. Bioluminescence imaging (BLI) was performed with
the IVIS 50 imaging system (Xenogen/PerkinElmer) at Washington University
Molecular Imaging Core. 5 min before anesthesia via isofluorane inhalation, mice
were injected intraperitoneally with a luciferin solution (150 mg/kg). Luciferase
activity was acquired by 10 s of photon imaging, two mice at a time. Mice were
continuously imaged before and each week after surgery (for 5 weeks). All images
Fig. 8 LDHA inhibition is efficacious in human articular chondrocytes. Medial and lateral cartilage samples were obtained from knee articular cartilage of
patients undergoing TKA (n= 12). Medial regions of articular cartilage were more severely damaged upon radiographic and visual analysis by surgeon,
while lateral regions were healthier regions of cartilage with little signs of OA. a–d LDHA, G6PD2, MMP13, and NFKBIZ gene expression was measured in
OA cartilage by qPCR. Gene expression was normalized to actin. Gene expression is displayed as fold change in medial cartilage sample relative to paired
lateral cartilage sample. Bars represent mean ± S.D. for n= 12 patient samples. e, f Primary human knee articular chondrocytes were treated with IL-1β
(10 ng/mL) for 24 h. Seahorse was performed to measure ECAR and OCR as previously stated. Bars represent mean ± S.D. for five wells. Data is
representative of one out of two experiments. g IHC was performed for IκB-ζ in healthy and OA human cartilage (arrows). Representative images of n=
3 samples are displayed. h–j Chondrocytes were isolated from human knee articular cartilage. Cells were treated with IL-1β (10 ng/mL) for 24 h in the
presence or absence of IKK2i (10 μM) or FX11 (40 μM). Gene expression of NFKBIZ, IL-6, and MMP13 was measured by qPCR, with bars representing
mean of technical duplicates. Results are representative of one out of two independent experiments with similar trends. a–d Two-tailed student’s t-test was
performed. p-values indicated in figure.
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were analyzed by Living Image 3.0 software (RRID: SCR_014247, PerkinElmer) for
luminescent intensity of the knee areas of the MLI side compared to the Sham side.
Micro-CT and X-ray analysis. Intact knee joint from different animals were
isolated, fixed overnight in 10% neutral buffered formalin (HT501128, Sigma)
followed by washing with phosphate buffer saline (PBS) three times and transfer to
70% ethanol (v/v). Bones were then scanned using Scanco Medical micro-CT
systems (Scanco, Wayne, PA, USA) at the core facility at the Musculoskeletal
Center at Washington University in St. Louis (St. Louis, MO). Briefly, images were
scanned at a resolution of 20 µm, slice increment 20 µm, voltage 55 kV, current 145
µA and exposure time of 200 ms. After scanning the knee joint area, three-
dimensional images were constructed. X-ray analysis of isolated knee joints were
performed using Faxitron UltraFocus 100 on automatic settings and at x5
magnification.
Transfection and viral infection. GFP and IKK2ca were cloned in retroviral pMX
constructs. For exogenous expression, relevant pMX-constructs were first trans-
fected into Plat-E cells using Xtreme Gene 9 (XTG9-RO, Roche), followed by
collection of virus-containing media for 2 days. Virus-containing media was later
used to transduce primary chondrocytes by replacing culture media with virus-
containing media in the presence of polybrene (5 ng/mL, TR-1003, Sigma) for 24 h.
Media was then changed to DMEM with 10% FBS after 24 h.
For adenoviral infection, chondrocytes were treated with adenoviral-eGFP
(VVC-U of Iowa 4) or adenoviral-Cre-eGFP (VVC-U of Iowa 1174) (University of
Iowa Viral Vector Core) at an MOI of 10 in the presence of polybrene (5 ng/mL,
Sigma) in media containing 5% FBS for 24 h. After 24 h, media was changed to
DMEM containing 10% FBS. For DCFDA experiments using floxed cells,
adenoviral-LacZ (VVC-U of Iowa 3554) and adenoviral-Cre (VVC-U of Iowa 5)
(University of Iowa Viral Vector Core) were used to avoid fluorescent overlap of
DCFDA and GFP.
Western blot analysis. Total cell lysates for protein analysis were prepared by
scraping cells in 1x Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA,
USA) containing protease/phosphatase inhibitor (ThermoFisher Scientific, Halt
Protease Phosphatase Inhibitor Cocktail). Blotting was performed using primary
antibodies for LDHA (Cat# PA5-27406, Invitrogen, 1:1000 dilution), LDHB
(14824-1-AP, Proteintech, 1:1000 dilution), IκB-ζ (Cat# 14-16801-82, Invitrogen,
1:1000 dilution), and Actin (Cat# A228, Sigma, 1:5000 dilution). Protein con-
centration was determined by BCA assay (Pierce) and equal amounts of protein
were loaded onto sodium dodecyl sulfate–polyacrylamide gel electrophoresis gel.
After wet transfer to nitrocellulose membrane using BioRad Transfer system using
1x transfer buffer, and blocking with 5% BSA in PBS-Tween (0.1% v/v) (PBST) for
1 h at room temperature, membranes were probed with specific primary antibody
primary antibodies diluted in 5% BSA in PBST overnight at 4 °C. Membranes were
washed three times with PBST and probed with secondary antibodies from LI-COR
(Odyssey Imager; donkey anti-rabbit/IRDye, 800CW/anti-goat/IRDye 800CW,
anti-mouse IRDye 680RD, Donkey anti-rat/IRDye 800CW, 1:10,000 dilution) for
1 h at room temperature. Membranes were then washed three times with PBST and
scanned using LI-COR Odyssey Imager (LI-COR Biosciences, Lincoln, NE, USA)
at low resolution using Licor software (RRID: SCR_014579).
Extracellular lactic acid measurement. Chondrocytes were cultured for 1 day
with IL-1β treatment (10 ng/mL) with appropriate experimental conditions in 24-
well plates containing 500 μL of DMEM containing 10% FBS. Supernatant media
was collected and centrifuged to separate cell debris and floating cells. Supernatant
was used immediately or stored at −80° C until lactic acid assay was performed to
measure secreted lactate in the media using a 1:20 dilution (Cat# 1200011002, Eton
Biosciences, L-Lactate Assay Kit I). Unconditioned DMEM with 10% FBS was used
as a control for subtracting background.
qPCR analysis. Trizol (Sigma) was added to samples to isolate mRNA from cell
culture samples and human articular cartilage samples. Chloroform was added at a
ratio of 0.2:1 to Trizol to samples, followed by centrifugation at 12,000 × g for 15
min. Aqueous layer was isolation and equal amount of 70% ethanol was added.
RNA was then isolated from this fraction using PureLink RNA mini kit (Cat#
12183025, Ambion, Grand Island, NY, USA) and complementary DNA (cDNA)
was prepared using High-Capacity cDNA Reverse Transcription kit (Cat# 4368814,
Applied Biosystems). qPCR was carried out on BioRad CFX96 real time system
using iTaq universal SYBR green super-mix (Cat#1725120, BioRad, Hercules, CA,
USA). mRNA expression was normalized using actin as a housekeeping gene. Full
list of primers is listed in Supplementary Table 1.
Measurement of cellular metabolism by seahorse. Primary chondrocytes were
plated in Seahorse XF96 plates at 50,000 cells per well and treated with IL-1β
(10 ng/mL) in the presence or absence of IKK2 inhibitor or FX11. After 72 h,
Seahorse assay was performed. For glycolysis stress test, cells were serum starved
for 1 h in glucose-free media containing treatments, and measurement of ECAR
and OCR was performed prior to and after sequential addition of glucose,
oligomycin and 2-DG with measurements performed every 5 min. For MitoStress
test, cells were incubated in glucose-containing media for 1 h containing treatments
and measurements were performed every 5 min prior to and after sequential
addition of oligomycin, FCCP and Rotenone/Antimycin A. Data was analyzed
using Wave software.
Measurement of intracellular ATP. Primary chondrocytes were plated in 96-well
plates at 5 × 104 and treated with IL-1β for 24 h. Lysates were collected and pro-
cessed according to luminescence-based ATP assay kit (Cat#K255, Biovision, ADP/
ATP ratio Assay kit). Assay was performed in 96-well plate. Luminescence was
measured using luminescent plate reader after 15 min. Data was collected and
processed using Gen5 software.
Measurement of NAD:NADH ratio in chondrocytes. Chondrocytes were treated
with IL-1β (10 ng/mL) for 36 h in the presence or absence of IKK2 inhibitor
(10 μM) or FX11 (40 μM). NAD and NADH levels were measured using
NAD/NADH quantitation colorimetric kit (K337, Biovision, Milpitas, CA, USA).
NAD:NADH ratio was measured for each sample. Assay was performed on 96-well
plate and values measured using colorimetric plate reader.
Measurement of GSH:GSSH ratio in chondrocytes. Murine chondrocytes were
treated with IL-1β (10 ng/mL) for 24 h in the presence of absence of FX11 (40 μM)
or 6-ANA (50 mM). GSSG and total glutathione levels were measured using
Glutathione Fluorometric Assay Kit (K264, Biovision, Milpitas, CA, USA).
Fluorescence was measured in fluorescence plate reader in 96-well format. GSH
levels were determined by subtracting GSSG levels from Total glutathione levels.
Mitochondrial biogenesis assay. Murine chondrocytes were treated with IL-1β
(10 ng/mL) for 24 h in the presence of absence of SC-514 (10 μM). Mitochondrial
biogenesis was measured using colorimetric Mitobiogenesis In-Cell ELISA kit
(Ab110217, Abcam, Cambridge, MA, USA). Colorimetric assay was performed in
96-well plate format.
Measurement of G6PD activity in chondrocytes. Primary chondrocytes were
plated in 6-well plates and treated with IL-1β for 24 h. Lysates were collected and
assay was performed in 96-well plate following protocol of G6PD activity colori-
metric assay kit (Cat# K751, Biovision, G6PD assay kit). Kinetic absorbance
measurements were performed for 1 h using microplate reader and data was
analyzed using Gen5 sotware. G6PD activity was derived by choosing activity
between two timepoints in the linear region of curves.
Measurement of NADPH levels. Primary chondrocytes were plated in 10 cm
dishes and treated with IL-1β for 24 h. Cell lysates were processed and NADPH
levels were measured using fluorometric NADP/NADPH assay kit (Cat# ab17672,
Abcam). Fluorescence was measured using microplate reader in black walled, clear
bottom plates (Fisher). Data was collected and processed using Gen5 software.
Quantification of ROS species. Primary chondrocytes were treated for 24 h in
DMEM media. Cells were washed two times with phenol red-free PBS, followed by
incubation with 10 μM DCFDA (Cat#D6883, Sigma) or 5 μM DHE (Cat# D7008,
Sigma) in PBS for 30 min, followed by two more washes with PBS. Cells were
incubated in 37 °C incubator for 1 h in PBS, followed by fluorescence measurement
using microplate reader using Ex/Em 495/525 for DCFDA and Ex/Em 480/576
for DHE.
RNA sequencing and analysis. Primary chondrocytes were cultured in the pre-
sence or absence of IL-1β (10 ng/mL) for 24 h. RNA was collected as stated above.
Samples were prepared according to library kit manufacturer’s protocol, indexed,
pooled, and sequenced on an Illumina HiSeq. Basecalls and demultiplexing were
performed with Illumina’s bcl2fastq software and a custom python demultiplexing
program with a maximum of one mismatch in the indexing read. RNA-seq reads
were then aligned to the Ensembl release 76 primary assembly with STAR version
2.5.1a. Gene counts were derived from the number of uniquely aligned unam-
biguous reads by Subread:featureCount version 1.4.6-p5. Isoform expression of
known Ensembl transcripts were estimated with Salmon version 0.8.2. Sequencing
performance was assessed for the total number of aligned reads, total number of
uniquely aligned reads, and features detected. The ribosomal fraction, known
junction saturation, and read distribution over known gene models were quantified
with RSeQC version 2.6.2.
All gene counts were then imported into the R/Bioconductor package EdgeR
and trimmed mean of M-values (TMM) normalization size factors were calculated
to adjust for samples for differences in library size. Ribosomal genes and genes not
expressed in the smallest group size minus one samples greater than one count-
per-million were excluded from further analysis. The TMM size factors and the
matrix of counts were then imported into the R/Bioconductor package Limma.
Weighted likelihoods based on the observed mean-variance relationship of every
gene and sample were then calculated for all samples with the
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voomWithQualityWeights. The performance of all genes was assessed with plots of
the residual standard deviation of every gene to their average log-count with a
robustly fitted trend line of the residuals. Differential expression analysis was then
performed to analyze for differences between conditions and the results were
filtered for only those genes with Benjamini–Hochberg false-discovery rate
adjusted p-values ≤ 0.05.
For each contrast extracted with Limma, global perturbations in known Gene
Ontology (GO) terms, MSigDb, and KEGG pathways were detected using the R/
Bioconductor package GAGE8 to test for changes in expression of the reported log2
fold-changes reported by Limma in each term versus the background log2 fold-
changes of all genes found outside the respective term. The R/Bioconductor
package heatmap3 was used to display heatmaps across groups of samples for each
GO or MSigDb term with a Benjamini–Hochberg false-discovery rate adjusted p-
value ≤ 0.05. Perturbed KEGG pathways where the observed log2 fold-changes of
genes within the term were significantly perturbed in a single-direction versus
background or in any direction compared to other genes within a given term with
p-values ≤ 0.05 were rendered as annotated KEGG graphs with the R/Bioconductor
package Pathview.
Statistical analysis. All experiments were repeated at least three times with similar
results, unless otherwise stated in the figure legend. All images of immunoblots are
representative of one of three experiments. Statistical analyses were performed
using appropriate statistical test using GraphPad Prism and graphs were generated
using Prism. Data from multiple experiments was displayed as mean ± S.E.M.
DCFDA, viability, and seahorse experiment data is displayed as mean ± S.D.
representative of one of multiple experiments. Multiple treatments were analyzed
by one-way ANOVA followed by Tukey’s test multiple comparisons test. Student’s
t-test was used for comparing two groups. Data from experiments was not com-
bined if values between experiments showed large variations, but the trends
remained the same between the tested conditions. Instead data is shown with
technical replicates from one experiment, but statistics were not performed on
technical replicates and no error bars are displayed for experiments with n < 3
replicates. Gene expression results from human OA cartilage was compared by
paired student’s t-test between patient’s lateral and medial cartilage. Animal
experiments were performed with age-matched, sex matched mice. p-values are
indicated where applicable.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA-sequencing data have been deposited in Gene Expression Omnibus (GEO) under
the primary accession code GSE148159. Other data that support the findings of this study
are available from the corresponding author upon reasonable request. Source data are
provided with this paper.
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